Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

NRG HN001/ Individualized Treatment for Naso-pharyngeal Carcinoma EBV positive/ Yuhchyau Chen

Research Question:
Does testing levels of the virus EBV in a patient with cancer of the nasopharynx help determine the best treatments?

Basic Study Information

Purpose:
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer.

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher:  Yuhchyau Chen

Study Contact Information

Study Coordinator: Therese Smudzin
Phone: +1 585-275-7848
Email: therese_smudzin@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search